Alzheimer´s Disease Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).
Study visits: Each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02245737 -
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT02360527 -
Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease
|
N/A | |
Completed |
NCT01225809 -
AD01 Follow up Extension Visit
|
N/A | |
Terminated |
NCT01117948 -
Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
|
Phase 2 | |
Terminated |
NCT01736579 -
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
|
Phase 3 | |
Completed |
NCT02501876 -
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT01695889 -
Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?
|
N/A | |
Completed |
NCT00608946 -
Treatment With Copper in Patients With Mild Alzheimer´s Dementia
|
Phase 2 | |
Terminated |
NCT02008513 -
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
|
Phase 2 | |
Completed |
NCT02224326 -
Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia
|
||
Terminated |
NCT01125683 -
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT01357629 -
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
|
N/A | |
Terminated |
NCT01524887 -
Phase 3 IGIV, 10% in Alzheimer´s Disease
|
Phase 3 | |
Completed |
NCT00692705 -
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
|
Phase 1 | |
Active, not recruiting |
NCT02623764 -
EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
|
||
Completed |
NCT00948259 -
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
|
Phase 1/Phase 2 |